1 |
Li J, Ling J, Yao C. Recent advances in NIR-II fluorescence based theranostic approaches for glioma. Front Chem 2022;10. [DOI: 10.3389/fchem.2022.1054913] [Reference Citation Analysis]
|
2 |
Hou M, Ye M, Liu L, Xu M, Liu H, Zhang H, Li Y, Xu Z, Li B. Azide-Locked Prodrug Co-Assembly into Nanoparticles with Indocyanine Green for Chemophotothermal Therapy. Mol Pharmaceutics. [DOI: 10.1021/acs.molpharmaceut.2c00452] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
3 |
Xia M, Guo Z, Liu X, Wang Y, Xiao C. A glutathione-responsive sulfur dioxide polymer prodrug selectively induces ferroptosis in gastric cancer therapy. Biomater Sci 2022. [PMID: 35727040 DOI: 10.1039/d2bm00678b] [Reference Citation Analysis]
|
4 |
Sun L, Zhao P, Chen M, Leng J, Luan Y, Du B, Yang J, Yang Y, Rong R. Taxanes prodrug-based nanomedicines for cancer therapy. J Control Release 2022;348:672-91. [PMID: 35691501 DOI: 10.1016/j.jconrel.2022.06.004] [Reference Citation Analysis]
|
5 |
Wang X, Zhao X, Zhong Y, Shen J, An W. Biomimetic Exosomes: A New Generation of Drug Delivery System. Front Bioeng Biotechnol 2022;10:865682. [DOI: 10.3389/fbioe.2022.865682] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
6 |
Das SS, Moitra I, Das S, Singh N, Verma PRP, Singh SK. Conventional to Nanoscale-Based Carrier Systems in the Management of Ovarian Cancer. Hormone Related Cancer Mechanistic and Nanomedicines 2022. [DOI: 10.1007/978-981-19-5558-7_5] [Reference Citation Analysis]
|
7 |
Li X, Chen L, Luan S, Zhou J, Xiao X, Yang Y, Mao C, Fang P, Chen L, Zeng X, Gao H, Yuan Y. The development and progress of nanomedicine for esophageal cancer diagnosis and treatment. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.01.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
|